미국 · 보도자료 · Anixa Biosciences, Inc. · 2026-10-01 12:35
난소암 CAR-T 임상 5코호트 두 번째 환자 투약 진행
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc....
